Replace fragmented assays:
one workflow for cell therapy assessment
Discover Nanolive’s cell therapy screening workflow, as we showcase the power of a single assay for assessing efficacy, mechanism, and failure modes of immune cell therapies. Using real data we show how to reduce time, costs and errors, by simplifying fragmented assays into a single process to accelerate screening and selection of therapies.
From activation to target engagement and killing, Nanolive’s revolutionary technology enables the identification of the most effective therapeutic candidates using live, label-free and automated analysis of effector cell activation, interactions, and killing. This session will present insights from nonadherent AML and CML models with gamma-delta T cells, and human CAR T cells, using the only high-resolution and automated system for quantifying the effector cell response in co-culture.
Stop screening immunotherapies with fragmented assays.
Understand activation, engagement, and killing dynamics in one experiment.
Workflow highlights:
- Detect death rate in effector and target cell populations
- Rank T cell therapies based on killing efficacy
- Effector cell exhaustion and activation status
- Identify mechanisms for T cell efficacy improvement
- Effector-tumor cell interactions
This event is ideal for biopharma professionals who are looking to:
- Increase reproducibility with scalable, automated analysis
- Accelerate drug screening and candidate selection with high-content data
- Reduce decision fatigue at the planning level
- Reduce data silos and complex integration and analysis
- Support more informed, unbiased decision-making with label-free data
Host
Matthias Schade
Field Application Specialist
Nanolive